 Sorrento Therapeutics Incs SRNE late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits omicron virus entry and replication in cell-based assays. ALERT Matt Maley just released his latest pick with an upside of over 100 in 2 years. 